Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;167(3):628-630.
doi: 10.1016/j.surg.2019.09.018. Epub 2019 Oct 14.

Current status and limitations of immunotherapy for breast cancer

Yoshihisa Tokumaru  1 , Daniel Joyce  1 , Kazuaki Takabe  2
Affiliations
Review

Current status and limitations of immunotherapy for breast cancer

Yoshihisa Tokumaru et al. Surgery. 2020 Mar.
No abstract available

PubMed Disclaimer

References

    1. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108–21. - PubMed
    1. Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405–11. - PubMed
    1. Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20:371–82. - PubMed
    1. Narayanan S, Kawaguchi T, Yan L, et al. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer. Ann Surg Oncol. 2018;25:2323–31. - PMC - PubMed
    1. Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471–5. - PMC - PubMed

Publication types

MeSH terms

Substances